DNTH · Dianthus Therapeutics, Inc.
$104.79
-0.22% last session
End-of-day data · updated 2026-07-25
Market cap
$6B
Enterprise value
$5B
Trailing P/E
—
Forward P/E
-22.3
Dividend yield
—
Beta
0.09
Avg volume
1M
Employees
0K
2D change
-0.88%
5D change
2.84%
10D change
3.96%
30D change
13.43%
60D change
19.64%
MTD change
15.14%
YTD change
152.05%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — DNTH
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-06
Latest call per bank · past 12 months
Wells Fargo
Overweight$135
+28.8% vs priceJefferies
Buy$81.00
-22.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-06 | Wedbush | Maintains | Outperform | $103 → $105 |
| 2026-04-09 | Wolfe Research | Initiates | Outperform | $0.00 → $98.00 |
| 2026-03-19 | Wells Fargo | Initiates | Overweight | $0.00 → $135 |
| 2026-03-12 | Wedbush | Maintains | Outperform | $80.00 → $103 |
| 2026-03-10 | Wedbush | Maintains | Outperform | $55.00 → $80.00 |
| 2026-03-10 | Raymond James | Upgrade | Outperform → Strong Buy | $63.00 → $123 |
| 2026-03-10 | Baird | Maintains | Outperform | $67.00 → $132 |
| 2026-03-10 | Clear Street | Maintains | Buy | $100 → $130 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-27
- RSI (14): RSI is 60 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 15.4% above the 50-day MA ($90.61).
- Price vs 200-day MA: Trading 61.2% above the 200-day MA ($64.86).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.33) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($105.72).
DNTH Price Chart
Loading chart for DNTH…
Fundamentals
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.